Context

DBV Technologies dual listed on Nasdaq since October 2014.

PEPITES phase III results released in October 2017 showed a 35.5% responder rate vs. 13.6% for the placebo at a 250ug dose (p=0.00001) with a strong safety profile.

FDA filing for Viaskin Peanut expected in 2018 H2.

Viaskin Milk phase 2 results released in February 2018 validated further the EPIT platform.

Equity raise to fund the development and commercialization of Viaskin Peanut and to advance development of other product candidates.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY.

Discover DBV Technologies

Hervé Ronin

Investment Banking

Cosme Rosellini

Investment Banking

Dr. Anne Moore

Investment Banking

Jean de Pracomtal

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center